Fruquintinib is a potent VEGFR inhibitor, and emerging studies suggest that VEGF signaling interacts with the TGF-β pathway (38), which plays a pivotal role in epithelial-mesenchymal transition (EMT) and tumor progression. Here, KDR is linked to neoplasm.